Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial.

ABSTRACT:

Importance

Heart failure with improved ejection fraction (HFimpEF), defined as prior left ventricular ejection fraction (LVEF) 40% or lower that has increased to greater than 40%, is understudied.

Objective

To examine mode of death and the association of dapagliflozin with reductions in cause-specific death in patients with HFimpEF.

Design, setting, and participants

This was a post hoc analysis from the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) randomized clinical trial, conducted from August 2018 to December 2020. The trial randomly assigned patients with HF with LVEF greater than 40%, New York Heart Association class II to IV symptoms, and elevated natriuretic peptides to treatment with dapagli

SUBMITTER: Vardeny O 

PROVIDER: S-EPMC10809142 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature